A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
Phase 3
45 Years
N/A
45 Years
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
Inclusion Criteria:
- Patients eligible for entry into the main ATAC trial (1033IL/0029)
- Not received any previous tamoxifen, for whatever reason
- Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6
years
- No previous endometrial ablation
Exclusion Criteria:
- Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section
4.4 of the main ATAC trial (1033IL/0029)
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Outcome Measure:
Withdrawl
Authority:
Australia: Department of Health and Ageing Therapeutic Goods Administration
Study ID:
1033IC/0029
NCT ID:
NCT00814125
Start Date:
June 1997
Completion Date:
December 2005
Related Keywords:
- Breast Cancer
- Endometrial
- Endometrial histological findings
- Breast Neoplasms
- Adenoma
Name | Location |
|---|
